The histological transformation from NSCLC to SCLC increases the therapeutic challenges in overcoming EGFR TKI resistance in LUAD; however, the molecular features modulated during transformation remain unclear [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.